tbuckley/cabot-search huggingface dataset:
Clinical Utility of Molecular Profiling in Higher Risk MDS Treated with Azacitidine: Can We Tailor Therapy Accordingly?
Authors: David Sallman, Eric Padron, Jinming Song, Mohammad Omar Hussaini, Christine Vaupel, Najla H Al Ali, Jeffrey E. Lancet, Jeff Hall, Alan F List, Rami S. Komrokji
Journal: Blood (2016)
Associations of Trimester-Specific Exposure to Bisphenols with Size at Birth: A Chinese Prenatal Cohort Study
Authors: Jie Hu, Hongzhi Zhao, Joseph M. Braun, Tongzhang Zheng, Bin Zhang, Wei Xia, Wenxin Zhang, Jiufeng Li, Yanqiu Zhou, Han Li, Jun Li, Aifen Zhou, Yiming Zhang, Stephen L. Buka, Simin Liu, Yang Peng, Chuansha Wu, Minmin Jiang, Wenqian Huo, Yingshuang Zhu, Kunchong Shi, Yuanyuan Li, Zongwei Cai, Shunqing Xu
Journal: Environmental Health Perspectives (2019)

BACKGROUND: Bisphenol A (BPA) is an endocrine disruptor that affects fetal growth in experimental studies.Bisphenol F (BPF) and bisphenol S (BPS), which have been substituted for BPA in some consumer products, have also shown endocrine-disrupting effects in experimental models.However, the effects of BPF and BPS on fetal growth in humans are unknown.OBJECTIVES: Our goal was to investigate trimester-specific associations of urinary concentrations of BPA, BPF, and BPS with size at birth.METHODS: The present study included 845 pregnant women from Wuhan, China (2013-2015), who provided one urine sample in each of the first, second, and third trimesters.Linear regressions with generalized estimating equations were applied to estimate trimester-specific associations of urinary bisphenol concentrations with birth weight, birth length, and ponderal index.Linear mixed-effects models were used to identify potential critical windows of susceptibility to bisphenols by comparing the exposure patterns of newborns in the 10th percentile of each birth anthropometric measurement to that of those in the 90th percentile.RESULTS: Medians (25th-75th percentiles) of urinary concentrations of BPA, BPF, and BPS were 1.40 (0.19-3.85), 0.65 (0.34-1.39), and 0.38 (0.13-1.11) ng/mL, respectively.Urinary BPA concentrations in different trimesters were inversely, but not significantly, associated with birth weight and ponderal index.Urinary concentrations of BPF and BPS during some trimesters were associated with significantly lower birth weight, birth length, or ponderal index, with significant trend p-values (p trend < 0:05) across quartiles of BPF and BPS concentrations.The observed associations were unchanged after additionally adjusting for other bisphenols.In addition, newborns in the 10th percentile of each birth anthropometry measure had higher BPF and BPS exposures during pregnancy than newborns in the 90th percentile of each outcome.CONCLUSIONS: Prenatal exposure to BPF and BPS was inversely associated with size at birth in this cohort.Replication in other populations is needed.
A phase Ib study of E7046 (AN0025) in combination with radiotherapy/chemoradiotherapy (RT/CRT) in preoperative treatment of rectal cancer
Authors: L. Wyrwicz, M.P. Saunders, M. Hall, J. Ng, V Bhagawati Prasad, N. Lautermilch, M.M. Rashford, J. Jin, S. Formenti, R. Glynne-Jones
Journal: Annals of Oncology (2019)
The final outcomes of study on combined therapy of adult patients with localized synovial sarcoma
Authors: K. Kozak, I. Lugowska, P. Teterycz, H M Kosela Paterczyk, T. Switaj, T. Goryn, W. Dziewirski, T. Morysinski, S. Falkowski, P. Rutkowski
Journal: Annals of Oncology (2019)
The safety assessment of crizotinib and alectinib from real-world data of 840 ALK-inhibitor naïve patients with NSCLC harboring ALK-rearrangement (WJOG9516L)
Authors: K. Kunimasa, K. Ito, T. Yamanaka, D. Fujimoto, M. Mori, K. Maeno, K. Tomomatsu, A. Tamura, H. Tanaka, S. Watanabe, S. Teraoka, O. Hataji, K. Suzuki, S. Hontsu, S. Hara, A. Bessho, A. Kubo, M. Okuno, K. Nakagawa, N. Yamamoto
Journal: Annals of Oncology (2019)
Analysis of gut microbiota in advanced non-small cell lung cancer (NSCLC) patients treated with immune-checkpoints blockers
Authors: F. Zhang, N. Dong, S. Gallach, S. Calabuig Fariñas, M. Mosqueda, E. Escorihuela, M. Meri, F. De Asís, A. Blasco, J. Garde, E. Jantus-Lewintre, C. Camps
Journal: Annals of Oncology (2019)
Dual inhibition of TGF-β and AXL as a novel treatment for colorectal cancer
Authors: D. Ciardiello, V. Belli, C. Cardone, P.P. Vitiello, G. Martini, L. Poliero, C. Borrelli, G. Arrichiello, V. Ciaramella, N. Matrone, G. Barra, V. De Falco, E.F. Giunta, F. Morgillo, T. Troiani, M. Terminiello, D. Melisi, F. Ciardiello, E. Martinelli
Journal: Annals of Oncology (2019)
Abstract 16627: Resource Utilization in Pediatric Patients Supported With Ventricular Assist Devices in the United States: A Multicenter Study From the Pediatric Interagency Registry for Mechanical Assisted Circulatory Support and the Pediatric Health Information System
Authors: Joseph W Rossano, Ryan S Cantor, Dingwei Dai, Pirouz Shamszad, Yuan-Shung Huang, Matthew Hall, Kimberly Y Lin, R. Erik Edens, P. Eugene Parrino, James K Kirklin
Journal: Circulation (2017)

Introduction: Few data exist on resource utilization with pediatric ventricular assist device (VAD) use. We aimed to describe hospital costs and lengths of stay (LOS) in a contemporary cohort of pe...
Discovery of a phosphatidylserine recognizing peptide and its utility in molecular imaging of tumor apoptosis
Authors: Jaehoon Pyo, Narendra Thapa, So-Yeon Kim, In-Sup So, Byung-Heon Lee, Rang-Woon Park, Ick-Chan Kwon, Kuiwon Choi, In-San Kim
Journal: Cancer Research (2008)

3723  The exposure of phosphatidylserine (PS) molecules from the inner to the outer leaflet of the plasma membrane has been recognized as a well-defined molecular epitope of cells undergoing apoptosis. Examination and monitoring of PS exposure is an extensively used molecular marker in noninvasive apoptosis imaging under a variety of clinical conditions, including the assessment of therapeutic anticancer agents and myocardial infarction. Herein, we report the identification of a PS-recognizing peptide which was identified by the screening of an M13 phage display peptide library. Repeated biopanning for a total of four rounds revealed a predominant enrichment of the phage clone displaying peptide sequence, named PSP-1 (46%). The identified phage clone showed increased binding to a number of apoptotic cells over non-apoptotic cells, and this binding was inhibited by both annexin V and synthesized peptide displayed on the phage. The binding of the fluorescein-labeled PSP-1 peptide to apoptotic vs. normal cells was assessed by both FACS analysis and fluorescence microscopy. Optical live animal imaging after the systemic administration of fluorescein-labeled PSP-1 peptide to tumor-bearing nude mice (H460 cells xenograft model) treated with a single dose of an anticancer drug (camptothecin) indicated enhanced peptide homing to the tumor. The histological examination of tumor tissues showed intense staining of the tumor vasculature and apoptotic tumor cells. With these results, the PSP-1 peptide is a novel PS-recognizing moiety which may possibly be developed into a molecular probe for the imaging of apoptosis in vivo including therapeutic assessment of cancer.
Use of mobile device technology to collect patient-reported symptoms during radiotherapy for head and neck cancer: A prospective feasibility study.
Authors: Aaron David Falchook, Gregg Tracton, Lori Stravers, Mary Fleming, Bryce B. Reeve, Ethan M. Basch, Bhishamjit S. Chera
Journal: Journal of Clinical Oncology (2015)

9599 Background: Accurate assessment of toxicity allows for timely delivery of necessary supportive measures during radiotherapy (RT) treatment for head and neck cancer. The purpose of this prospective trial is to evaluate the feasibility of using mobile device technology to collect daily patient reported symptoms. Methods: A HIPAA-secure mobile application was developed to allow patients receiving RT for head and neck cancer to report symptom severity in five domains (fatigue, pain, nausea/vomiting, decreased appetite, anxiety) using the Patient Reported Symptom Monitoring System questionnaire. Patients were asked to report symptoms using a smartphone and/or tablet at least once daily during treatment or more often as needed. Patient surveys regarding use of mobile devices were obtained after completion of RT. Descriptive statistics, linear regression, and Fisher's exact test were used to examine factors associated with symptom reporting. Results: 22 patients enrolled and 1 withdrew consent. A total of 921 symptom reports were collected during treatment. Median treatment duration was 45.5 days (interquartile range [IQR] 42-49). The median number of reports submitted per patient was 33.5 (IQR 21-54). Median reporting compliance (defined as number of days with report / duration between enrollment and end of RT) was 71% (IQR 44-81). There were no significant associations between reporting compliance and patient characteristics or symptom severity. Timing of symptom reporting is summarized (Table). Patients reported high levels of satisfaction with use of mobile devices to report symptoms. Conclusions: It is feasible and convenient for patients to use mobile devices to continuously report symptoms throughout an entire course of RT for head and neck cancer, including nights and weekends. Future studies will evaluate the impact of mobile device symptom reporting on improving patient outcomes. Day of Week Reports per Patient (Median) IQR Sun 5 3-7 Mon 5 3-8 Tue 5 4-8 Wed 5 3-8 Thurs 5.5 4-7 Fri 6 3-10 Sat 4 2-6 Week of Treatment 1 7 3-10 2 6 5-7 3 6 5-9 4 6.5 4-9 5 6 4-8 6 5 3-7 7 6.5 5-12 Report During Clinic Hours (7AM-5PM, Weekdays) Non-clinic hours 17 10-30 Clinic Hours 14.5 9.5-27.5
A phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1
Authors: D.-Y. Oh, L.-T. Chen, A.R. He, T. Okusaka, S. Qin, S. Chin, N. Rokutanda, H. Uchinda, A. Vogel, J.W. Valle, H. Kim
Journal: Annals of Oncology (2019)
Determinants of response of HER2+ gastric cancer (GC) vs gastroesophageal junction adenocarcinoma (GEJ) to margetuximab (M) plus pembrolizumab (P) post trastuzumab (T)
Authors: H. Park, H. Uronis, Y.-K. Kang, M.C.H. Ng, P. Enzinger, K.W. Lee, S. Rutella, S.E. Church, J. Nordstrom, K. Knutson, C. Erskine, T. Wu, J. Yen, A. Franovic, J. Muth, M. Rosales, J. Vadakekolathu, J. Davidson-Moncada, Y.-J. Bang, D.V. Catenacci
Journal: Annals of Oncology (2019)
Carboxylesterase-Cleavable Biotinylated Nanoparticle for Tumor-Dual Targeted Imaging
Authors: Peiyao Chen, Wen Kuang, Zhen Zheng, Shuye Yang, Yaling Liu, Lanhong Su, Kui Zhao, Gaolin Liang
Journal: Theranostics (2019)

Near-infrared (NIR) nanoprobes with fluorescence "Turn-On" property are advantageous in cancer diagnosis but, to the best of our knowledge, "smart" nanoprobe that simultaneously targets both biotin receptor and carboxylesterase (CES) for HepG2 tumor-dual targeted imaging has not been reported.Methods: Using CBT-Cys click condensation reaction, we rationally designed a "smart" NIR fluorescence probe H2N-Cys(StBu)-Lys(Biotin)-Ser(Cy5.5)-CBT(NIR-CBT) and used it to facilely prepare the fluorescence-quenched nanoparticle NIR-CBT-NP.Results: In vitro results indicated that, after NIR-CBT-NP was incubated with CES for 6 h, its fluorescence was turned "On" by 69 folds.Cell experiments verified that NIR-CBT-NP was uptaken by HepG2 cells via biotin receptor-assisted endocytosis and its fluorescence was turned "On" by intracellular CES hydrolysis.Moreover, NIR-CBT-NP was successfully applied to image both biotin receptor-and CES-overexpressing HepG2 tumors.Conclusion: Fluorescence-quenched nanoparticle NIR-CBT-NP was facilely prepared to actively target biotin receptor-overexpressing HepG2 cancer cells and turn the fluorescence "On" by intracellular CES hydrolysis for tumor-dual targeted imaging.We anticipate that our fluorescence "Turn-On" nanoparticle could be applied for liver cancer diagnosis in clinic in the near future.
Novel cyclin dependent kinase (CDK) inhibitors induce down regulation of Mcl-1 and apoptosis in multiple myeloma cells
Authors: David E. Maccallum, Jean Melville, Kathryn Watt, Wayne Jackson, Stuart Wilson, Edward McDonald, Paul Workman, Simon R. Green
Journal: Cancer Research (2006)

2069  Multiple myeloma is a disease of malignant B-cells that have extended survival and a low proliferation rate which accumulate in the bone marrow causing osteolytic bone lesions. Treatment with current chemotherapeutic agents initially reduces tumour burden but the disease remains incurable, with the average patient survival time being three years. Therefore, there is an urgent need for novel therapies ideally based on an understanding of the biology of the disease. One area of interest is that of cyclin dependent kinases that regulate two main cellular processes essential for malignant cell survival; cell cycle progression and transcription. These kinases are good cellular targets for anti-neoplastic drugs. Seliciclib (CYC202, R-roscovitine) is a CDK inhibitor, currently in clinical trials, that principally targets CDK2, CDK7 and CDK9 and shows potent activity against multiple myeloma cells (MacCallum et al., 2005. Cancer Res. 65 pp5399). Selicliclib acts in part by inhibiting the kinases that phosphorylate the C-terminal domain (CTD) of RNA polymerase II resulting in the inhibition of transcription and down regulation of mRNAs and proteins with short half-lives. One such protein is the anti-apoptotic Mcl-1 that is essential for multiple myeloma cell survival. This study characterises three novel CDK inhibitors, two tri-substituted purines and a 2-anilino-4-(thiazol-5-yl)-pyrimidine that have greater potency in both in vitro kinase assays and against cells in culture. Upon treatment of multiple myeloma cells, all three compounds rapidly inhibit phosphorylation of the CTD of RNA polymerase II at phospho-serine 2, accompanied by an equivalent effect on gene expression to that seen with seliciclib treatment. These changes include down regulation of Mcl-1 at both the mRNA and protein level resulting in induction of apoptosis; detectable by PARP cleavage and TUNEL. The results demonstrate that these CDK inhibitors work by a similar mechanism to seliciclib but with increased potency. Furthermore, they provide scientific rationale for their continued pre-clinical development.
CRISPR/Cas9 gene-editing strategies in cardiovascular cells
Authors: Eva Vermersch, Charlène Jouve, Jean-Sébastien Hulot
Journal: Cardiovascular Research (2019)

Abstract Cardiovascular diseases are among the main causes of morbidity and mortality in Western countries and considered as a leading public health issue. Therefore, there is a strong need for new disease models to support the development of novel therapeutics approaches. The successive improvement of genome editing tools with zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and more recently with clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 (Cas9) has enabled the generation of genetically modified cells and organisms with much greater efficiency and precision than before. The simplicity of CRISPR/Cas9 technology made it especially suited for different studies, both in vitro and in vivo, and has been used in multiple studies evaluating gene functions, disease modelling, transcriptional regulation, and testing of novel therapeutic approaches. Notably, with the parallel development of human induced pluripotent stem cells (hiPSCs), the generation of knock-out and knock-in human cell lines significantly increased our understanding of mutation impacts and physiopathological mechanisms within the cardiovascular domain. Here, we review the recent development of CRISPR–Cas9 genome editing, the alternative tools, the available strategies to conduct genome editing in cardiovascular cells with a focus on its use for correcting mutations in vitro and in vivo both in germ and somatic cells. We will also highlight that, despite its potential, CRISPR/Cas9 technology comes with important technical and ethical limitations. The development of CRISPR/Cas9 genome editing for cardiovascular diseases indeed requires to develop a specific strategy in order to optimize the design of the genome editing tools, the manipulation of DNA repair mechanisms, the packaging and delivery of the tools to the studied organism, and the assessment of their efficiency and safety.
The Biological and Biographical Basis of Precision Medicine
Authors: Gabriella Lobitz, Katrina Armstrong, John Concato, Burton H. Singer, Ralph I. Horwitz
Journal: Psychotherapy and Psychosomatics (2019)

Construction of a patient narrative (case history) is a core strategy in the care of patients. Recent advances in biomarker identification and digital sensors to monitor physiological and behavioral features have made constructing a case history more complex. Notably, however, although a biological profile is increasingly a part of the patient’s profile, an analogous patient-based biographical (life experience) profile is typically overlooked. Evolving concepts such as allostasis and allostatic load refer to processes promoting stability of physiological systems in the presence of diverse life experiences. Integrating details of both biology and biography is a goal of “precision medicine.” In this review, we describe how complex interactions between biology and biography affect disease risk and treatment response and highlight a strategy to develop narratives that establish the integration of biology and biography as the scientific basis for precision medicine.
Arterial Grafts for Coronary Bypass
Authors: Mario Gaudino, Faisal G. Bakaeen, Umberto Benedetto, Antonino Di Franco, Stephen Fremes, David Glineur, Leonard N. Girardi, Juan Grau, John D. Puskas, Marc Ruel, Derrick Y. Tam, David P. Taggart, Charalambos Antoniades, Carlo Patrono, Thomas A. Schwann, James Tatoulis, Robert F. Tranbaugh
Journal: Circulation (2019)

Observational and randomized evidence shows that arterial grafts have better patency rates than saphenous vein grafts (SVGs) in coronary artery bypass grafting. Observational studies suggest that the use of multiple arterial grafts is associated with longer postoperative survival, but this must be interpreted in the context of treatment allocation bias and hidden confounders intrinsic to the study designs. Recently, a pooled analysis of 6 randomized trials comparing the radial artery with the SVG as the second conduit and the largest randomized trial comparing the use of single and bilateral internal thoracic arteries have provided apparently divergent results about a clinical benefit with the use of &gt;1 arterial conduit. However, both analyses have methodological limitations that may have influenced their results. At present, it is unclear whether the well-documented increased patency rate of arterial grafts translates into clinical benefits in the majority of patients undergoing coronary artery bypass grafting. A large randomized trial testing the arterial grafts hypothesis (ROMA [Randomized Comparison of the Clinical Outcome of Single Versus Multiple Arterial Grafts]) is underway and will report the results in a few years.
Combination therapy with checkpoint inhibitors for first-line treatment of advanced renal cell carcinoma: A systematic review and meta-analysis of randomized controlled trials
Authors: K.Z. Thein, F. Mogollon-Duffo, S. Swarup, A. Sultan, R. Yendala, N. Jahan, M. Quirch, S. Ball, T Win Htut, N. D’Cunha, S. Rehman, F. Hardwicke, S. Awasthi, L. Tijani
Journal: Annals of Oncology (2019)
Abstract 10886: Targeting Endoglin Activity Improves Survival and Reduces Right Ventricular Fibrosis in a Murine Model of Pulmonary Arterial Hypertension
Authors: Navin K Kapur, Xiaoying Qiao, Emily E Mackey, Vikram Paruchuri, Gerard H Daly, Prerna Nepali, Mark J Aronovitz, Michelle Letarte, Richard H Karas
Journal: Circulation (2012)

Right ventricular (RV) function is a major determinant of clinical outcomes in pulmonary hypertension (PH). Transforming growth factor beta1 (TGFb1) is a profibrogenic cytokine that signals via eff...
CONTESSA TRIO: A multinational, multicenter, phase II study of tesetaxel plus 3 different PD-(L)1 inhibitors in patients with metastatic triple negative breast cancer (TNBC) and tesetaxel monotherapy in elderly patients with her2- metastatic breast cancer (MBC)
Authors: S.M. Tolaney, J.L. Blum, I. Bondarenko, A. Chan, N. DaCosta, Y.-H. Feng, Y. Izarzugaza, S.-B. Kim, M.-C. Liu, M. Oliveira, S.G.W. Ow, M. Pavic, M.E. Peréz Lopéz, H.S. Rugo, L. Schwartzberg, A. Stradella, S. Kroll, J. O’Connell, T. Wei, E.A. Mittendorf
Journal: Annals of Oncology (2019)
Image Gallery: Giant rhinophyma
Authors: Y.‐T. Qian, J.‐Y. Ma, S. Vano‐Galvan, D.‐L. Ma
Journal: British Journal of Dermatology (2019)

Dear Editor, A 59-year-old man presented with an 8-year history of asymptomatic progressive nose enlargement. A large pedunculated mass measuring 8 cm in diameter with dilated pilosebaceous pores was present on the nose, obstructing both nostrils (a, b). The mass had caused worsening shortness of breath during the previous year. It exhibited no ulceration or bleeding. The patient also had a 30-year history of alcoholism. The mass was completely excised and a skin graft was applied. The patient's breathing was restored to normal postoperatively. The excised tissue showed features consistent with rhinophyma. The outcome was satisfactory at 2 years, with an acceptable degree of scarring and restoration of normal nasal architecture (c, d). No recurrence was observed after 4 years of follow-up.
Combined androgen blockade in patients with advanced androgen receptor-positive salivary gland carcinoma: Exploratory biomarker analyses
Authors: C. Fushimi, D. Kawakita, H. Takahashi, T. Nagao, H. Hirai, N. Saigusa, T. Masubuchi, T. Matsuki, T. Okada, D. Baba, K. Miura, T. Saotome, Y. Tada
Journal: Annals of Oncology (2019)
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (CC): Updated analysis of stage II disease from the AVANT phase III randomized trial by the GERCOR group
Authors: A. De Gramont, J. Henriques, B. Baruch, T.W. Kim, M. Martinez-Villacampa, J. Gallego-Plazas, A. Cervantes, K. Shim, D.J. Jonker, V. Guerin-Meyer, L. Mineur, M. Banzi, A. Dewdney, T Sirisingha Dejthevaporn, H.J. Bloemendal, A.D. Roth, P. Thompson, M. Moehler, E Aranda Aguilar, T. André
Journal: Annals of Oncology (2019)
Final results of scalp cooling for hair preservation: A single- institution prospective study
Authors: D. Loparco, L. Orlando, M. Caloro, C. Caliolo, A. Quaranta, P. Schiavone, P. Fedele, M. Rendini, R. Varriano, A. Morleo, L.L. Falcone, G. Lotti, M. Cinefra, P. Ferrara, P. Rizzo, A. Marino, N. Calvani, E. Mazzoni, M. D’Amico, S. Cinieri
Journal: Annals of Oncology (2019)